Biogen's Revolutionary Multiple Sclerosis Treatment Clears First Hurdle
Biogen's 48% return over the last 12 months can largely be chalked up to investor optimism surrounding its oral multiple sclerosis drug Tecfidera (formerly referred to as BG-12). Today, the company happily announced that the EU's CHMP recommended approval for the drug's use in Europe. With an FDA decision on this same drug just around the corner, could Tecfidera soon be available to patients on both sides of the Atlantic?
In the following video, Motley Fool health-care analyst Max Macaluso discusses what this decision means for Biogen, and how this drug might compete with the current market leaders in the multiple sclerosis space.
What macro trend was Warren Buffett referring to when he said,This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The article Biogen's Revolutionary Multiple Sclerosis Treatment Clears First Hurdle originally appeared on Fool.com.Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.